Breast Cancer Research and Treatment 1993: Vol 26 Index

7 Pages·1993·1.1 MB·English

Breast Cancer Research and Treatment 26: 299-300, 1993.
© 1993 Kluwer Academic Publishers. Printed in the Netherlands.
Author index, Volume 26
Adkins D S-3 Dunphy F S-3 Kinishita K 67
Allred DC 191, 225 Kitagawa H 67
Amadori D 7 Eckhardt S 41 Kodama H 55
Azavedo E 207 Elledge RM 191, 225 Koenders PG 289
Elliott RL 77 Kornek G 49
Ballerini P 1 Elton RA 89 Krieg SL 191
Bélanger A 253 Encarnacion C 237 Kwasny W 49
Bearman SI S-11, S-19
Benedix MG 191 Ferrari L 1 Labrie F 253
Benraad ThJ 289 Fioravanti L 275 Lehrer SP 175
Benz CC 181 Franco RS 217 Lei Y 163
Berland E 283 Fuqua SAW 117, 191, 225, LeMaistre CF S-1
Bezwoda WR 247 237 Lepage M 253
Bolla M 283 Lewin A 101
Brandt ME 15 Greene GL 191 Lekeso
Brufman G 101 LiS 253
Haider K 49 Lower EE 217
Cappelletti V 7, 275 HamertonJ 149 Luce MC 181
Chambaz EM 283 Harada T 55
Chedin M 283 Head JF 77 Marron-Charriere J
Chetty U 89 Hennequin E 267 Martelo OJ 217
Ciocca DR 237 Hill BT 23 Martinetti A 1
Clark GM 225, 237 Holm L-E 207 Matthes S S-11
CétéJ 253 Horwitz KB 119 McCoy JL 77
Colonna M 283 McGuire WL 191,
Coradini C 275 Ichinose Y 55 zat
Correale M 7 Mérand Y 253
Covey DF 15 Jack W 89 Meyers S S-11, S-19
Jardillier J-C 267 Miksicek RJ 163
Daidone MG 7 Jiang S-Y 139 Miller MA 217
Dajee D 247 Jones RB S-11, S-19 Miller WR 89
de Goeij CCJ 289 Jones RJ S-31 Miodini P 275
Delvincourt C 267 Jordan VC 139 MiyazakiI 67
Depisch D 49 Mizukami Y 67
Di Fronzo G 7, 275 Kahan Z 41 Montgomery PA 181
Dolci S 1 Kan N 55 Mor-YosefS 101
Dorembus D 101 Kaufmann M 181 Moriguchi Y 55
Dotzlaw H 149 Kennedy MJ S-31 Murphy LC 149
Duca P 1 Kienhuis CBM 289
Dufton C S-11 Kinami S 67 Nawaz Z 191
300 Author index, Vol. 26
Nilsson B_ 207 Rochefort H 107 Svane G 207
Noguchi M 67 Rostaing-Puissant B 283 Sziics M 41
Nordevang E 207 Ruedl C 275
Takamura H 67
Satoh K 55 Thomas M 67
O’Malley BW 191
Schachter BS 175 Thorpe S 107
Ohgaki K 55
Scheithauer W 49
Oriana S 1
Schenk T 49 Ulrich SJ 95
Osborne CK 237
Schmutzler RK 175 Uziely B 101
SchwarzJ 149
Paradiso A 7
Schweitzer M 95 Velasquez W S-3
Parker CJ 139
Scott GK 181 Veneroni S 7
Parker MG 131 SecretoG | Venturelli E 1
Petruska P S-3
Seymour L 247 Vescernyés M 41
Pirker R 49
Shpall EJ S-11, S-19
Pourny C 267
Shyamala G 95 Wang Y 163
Puett D 15
Silvestrini R 7, 275 Watson DMA 89
Pujol P 225
Sluyser M 289 Whelan RDH 23
Purdy M S-19
Souvignet C 283 Williams SF S-25
Spencer V S-3
Rabin JM 175 Spitzer G S-3 Yamasaki S 55
Ravdin PM 110 Stemmer SM _ S-11, S-19
Riccobon A 7 Sugie T 55 Zimniski SJ 15
Breast Cancer Research and Treatment 26: 301-305, 1993.
© 1993 Kluwer Academic Publishers. Printed in the Netherlands.
Subject index, Volume 26
4-hydroperoxycyclophosphamide induction of autologous GVHD and antitumor
in marrow purging S-19-—S-23 activity S-31-S-40
preparative drug regimens S-3—S-9
adoptive immunotherapy
for liver metastases 55-65 cathepsin D
alternative splicing as a prognostic factor (discussion) 107-111
and estrogen receptor exon-skipping variants immunohistochemical determination and other
163-174 prognostic factors 7-13
and estrogen receptor variants 149-161 CD34+ selection
amifostine accelerated marrow engraftment S-19—S-23
in marrow purging S-19-S-23 chemotherapy
aneuploidy dose-intensive (minisymposium) S-1—S-40
see ploidy mdrl gene expression in primary vs. metastatic
antiestrogens tumors 267-274
ER point mutation changes structure-function navelbine and mitomycin C in second line
relationship 139-147 treatment 49-53
pure steroidal antiestrogens and ER dimerization pharmacokinetics at high doses S-11—S-17
and half-life 131-137 pharmacokinetics in directing drug dosing
responses, and estrogen receptor variants 117- S-11-S-17
118 tandem non-cross-resistant combinations
see also tamoxifen S-3-S-9
aromatase inhibitors cisplatin
10-propargylestr-4-ene-3,17-dione in rat DMBA BCNU toxicity increase at high doses
tumors 15-21 S-11-S-17
autologous bone marrow support in tandem non-cross resistant chemotherapy
see bone marrow transplantation combinations S-3—S-9
autologous tumor killing activity cyclic AMP binding proteins
in immuno-chemotherapy for liver metastases and prognosis 89-94
55-65 cyclophosphamide
in mobilizing peripheral blood progenitor cells
B-lymphocyte responses S-25-S-29
to pokeweed mitogen and tumor antigens in in tandem non-cross resistant chemotherapy
breast cancer patients 77-88 combinations S-3—S-9
BCNU pharmacokinetic interactions at high doses
toxicity increase by high-dose cisplatin S-11-S-17
S-11-S-17 to augment immunotherapy response 55-65
bone marrow transplantation cyclosporine A
accelerated engraftment with G-CSF, purging, induction of GVHD and antitumor activity
and CD34+ selection S-19-S-23 S-31-S-40
302 Subject index, Vol. 26
cytoxan estrogen receptor (cont.)
see cyclophosphamide association with hsp90 levels 95-100
by both ligand binding and immunohisto-
Depo-Provera (medroxyprogesterone acetate, MPA) chemistry, in tamoxifen resistance 237-246
controlled release MPA, inhibition of DMBA rat dimerization, half-life, and pure antiestrogens
mammary tumors 253-265 131-137
diet exon-skipping variants 163-174
fat intake and mammographic parenchymal genetic polymorphism associated with spon-
pattern 207-215 taneous abortion 175-180
DMBA rat mammary tumors loss in drug but not X-ray induced drug resis-
regression by a new aromatase inhibitor 15-21 tance 23-39
DNA ploidy non-DNA-binding but immunoreactive variants
see ploidy in breast tumors 181-189
dose-intensive therapy point mutation changes antiestrogen structure-
in breast cancer (minisymposium) S-1—S-40 function relationship 139-147
drug resistance possible variants in ER+/PgR— breast tumors
mdrl gene expression in primary vs. metastatic 191-202
tumors 267-274 truncated variants and alternative splicing 149-
X-ray vs. drug induced resistance patterns in 161
MCF-7 cells 23-39 variants in ER-positive and nominally ER-
negative cell lines 163-174
EGF receptor estrogen response element
downregulation by ER in hormone dependent non-binding ER variants in breast tumors 181-
tumors 289-295 189
inverse correlation with EGF-like activity in tumor protease activity mimicking non-DNA-
tumor specimens 41-47 binding ER 191-202
endocrine therapy etoposide
controlled release MPA, inhibition of DMBA rat in tandem non-cross resistant chemotherapy
mammary tumors 253-265 combinations S-3-S-9
regression of rat DMBA tumors by a new
aromatase inhibitor 15-21
fat intake
resistance and molecular variants of ER and PR
and mammographic parenchymal pattern 207-
119-130
ZS
tamoxifen resistance vs. true ER status 237-246
endometrium
proliferative changes with long-term tamoxifen G-CSF
101-105 accelerated engraftment of hematopoietic pro-
epidermal growth factor genitor cells S-19-S-23
see EGF in mobilizing peripheral blood progenitor cells
estrogen receptor S-25-S-29
abnormalities in breast cancer (special issue) graft-versus-host disease (GVHD)
117-202 induction and antitumor activity S-31—-S-40
and EGF receptor in hormone dependent vs. growth factors
independent tumors 289-295 paracrine interactions between hormone
and immunohistochemical localization of dependent and independent cell lines 275-
cathepsin D 7-13 281
Subject index, Vol. 26 303
heat shock proteins interferon gamma
hsp27 loss in drug but not X-ray induced drug augmentation of GVHD induction and antitumor
resistance 23-39 activity S-31-S-40
hsp90 associated with estrogen receptor 95-100 interleukin-2
Helix pomatia lectin (HPA) in immuno-chemotherapy for liver metastases
binding as a prognostic factor 67-75 55-65
hematopoietic cell support
see bone marrow, peripheral blood stem cells
keoxifene (antiestrogen)
high-dose chemotherapy
ER point mutation changes structure-function
in breast cancer (minisymposium) S-1—S-40
relationship 139-147
hormone dependence
and EGF receptor levels 289-295
paracrine interactions of dependent and indepen-
LINE-1 sequences
dent cell lines 275-281
in alternatively spliced ER variants 149-161
hormone resistance
lymphocyte responses
and molecular variants of ER and PR 119-130
to tumor antigens and general stimulators in
ER point mutation changes antiestrogen
breast cancer patients 77-88
structure-function relationship 139-147
vs. ER status by both ligand binding and
immunohistochemistry 237-246 mammographic parenchymal pattern
HPA and dietary fat intake 207-215
see Helix pomatia lectin binding marrow purging
4-hydroperoxycyclophosphamide 4-hydroperoxycyclophosphamide/amifostine
in marrow purging S-19-S-23 treatment S-19-S-23
MCF-7 cells
ICI 164384 drug vs. X-ray induced drug resistance patterns
pure antiestrogens and ER dimerization and half- 23-39
life 131-137 mdrl gene
ICI 182780 expression in primary vs. metastatic tumors
pure antiestrogens and ER dimerization and half- 267-274
life 131-137 medroxyprogesterone acetate (MPA)
IGF-I (insulin-like growth factor I) controlled release MPA, inhibition of DMBA rat
and paracrine interactions between hormone mammary tumors 253-265
dependent and independent cell lines 275- microspheres, poly[DL-lactide-co-glycolide]
281 controlled release MPA, inhibition of DMBA rat
immuno-chemotherapy mammary tumors 253-265
for liver metastases — immunological mitomycin C
parameters 55-65 and navelbine in second line treatment 49-53
immunohistochemistry mitoxantrone
quantitative cathepsin D, vs. other prognostic in tandem non-cross resistant chemotherapy
factors 7-13 combinations S-3—S-9
immunological parameters mixed lymphocyte tumor reaction
in patients with primary breast cancer vs. liver in immuno-chemotherapy for liver metastases
metastases 55-65 55-65
lymphocyte responses in breast cancer patients molecular variants
77-88 estrogen receptor (special issue) 117-202
304 Subject index, Vol. 26
multidrug resistance (MDR) progestin resistance
mdrl gene expression in primary vs. metastatic and molecular variants of ER and PR 119-130
tumors 267-274 progestin therapy
see also drug resistance controlled release MPA, inhibition of DMBA rat
mammary tumors 253-265
natural killer cell activity prognostic factors
in immuno-chemotherapy for liver metastases cathepsin D, by immunohistochemistry 7-13
55-65 cathepsin D (discussion) 107-111
navelbine cyclic AMP binding proteins 89-94
and mitomycin C in second line treatment 49- EGF receptor vs. EGF-like activity in tumor
53 specimens 41-47
nodal status Helix pomatia \ectin binding 67-75
and Helix pomatia lectin binding 67-75 p53 gene alterations 225-235
phosphotyrosine and tyrosine kinase 217-224
OK-432 (streptococcal immune stimulant) platelet derived growth factor in tumor 247-252
in immuno-chemotherapy for liver metastases tyrosine kinase activity 283-287
55-65 urinary testosterone 1-6
proliferative rate
P-glycoprotein by thymidine labelling, and cathepsin D 7-13
see drug resistance protein tyrosine kinase
p53 see tyrosine kinase
gene alterations and prognosis 225-235 pS2
paracrine interactions loss in drug-induced but not X-ray-induced drug
co-culture of hormone dependent and indepen- resistance 23-39
dent cell lines 275-281 pulmonary toxicity
peripheral blood lymphocytes and high-dose drug interactions S-11—S-17
in immuno-chemotherapy for liver metastases purging
55-65 4-hydroperoxycyclophosphamide/amifostine
peripheral blood progenitor cells treatment of marrow S-19-S-23
in reconstitution after high-dose chemotherapy
S-25-S-29
recurrence
pharmacokinetics
urinary testosterone as a marker 1-6
high-dose interactions of cisplatin and BCNU
recurrence risk
S-11-S-17
see prognostic factors
phosphotyrosine
RNA splicing
elevation in breast cancer, by immunohisto-
and estrogen receptor variants 117-118
chemistry 217-224
RU 39,411 (antiestrogen)
platelet derived growth factor (PDGF)
ER point mutation changes structure-function
in tumor tissue, vs. prognosis 247-252
relationship 139-147
ploidy
and Helix pomatia lectin binding, nodal status
67-75 single-stranded conformation polymorphism analysis
progesterone receptor p53 gene alterations and prognosis 225-235
and hsp90 levels 95-100 splicing variants
isoforms, antagonists, and function 127-128 estrogen receptor and LINE-1 sequences 149-
status in hormone resistant tumors 237-246 161
Subject index, Vol. 26
spontaneous abortion thiotepa
association with estrogen receptor genetic in tandem non-cross resistant chemotherapy
polymorphism 175-180 combinations S-3—S-9
stem cell transplantation toxicity
preparative drug regimens S-3-—S-9 and pharmacokinetics at high doses S-11—S-17
stem cells tumor antigens
accelerated engraftment by CD34+ selection T- and B-lymphocyte responses in breast cancer
S-19-S-23 patients 77-88
tyrosine kinase
T-cell growth factor activity and prognosis 283-287
in immuno-chemotherapy for liver metastases elevation in breast cancer 217-224
55-65
T-lymphocyte responses
ultrasound
to phytohemagglutinin and tumor antigens in
in evaluation of endometrial changes with long-
breast cancer patients 77-88
term tamoxifen 101-105
tamoxifen
urinary markers
and endometrial proliferative changes 101-105
testosterone and recurrence risk 1-6
ER point mutation changes structure-function
relationship 139-147
VP-16
resistance and molecular variants of ER and PR
see etoposide
119-130
resistance and true ER status 237-246
testosterone WR-2721
prognostic factor in urine 1-6 see amifostine
TGFa (transforming growth factor alpha)
and paracrine interactions between hormone ZR-75-1 cells
dependent and independent cell lines 275- drug vs. X-ray induced drug resistance patterns
281 23-39